ClinicalTrials.gg
RecruitingNCT04723485Updated May 13, 2025

Evaluation Study: Obsessive-compulsive Disorders in Childhood and Young Adulthood

An observational study in Obsessive-compulsive Disorder, sponsored by Susanne Walitza. Recruiting at 1 site in Switzerland. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Susanne Walitza · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
625
Ages
4 Years to 18 Years
Sex
All
01

Study summary

Obsessive-compulsive disorders are very damaging illnesses that can already manifest in childhood and adolescence. With an average prevalence from 1 - 3%, they are one of the most frequently diagnosed psychiatric illness in these age groups. With the further use of data, the treatment success can be significantly improved; causal variables/predictors can be recognized, understood and taken carefully into account. The anticipated incremental knowledge will ultimately help children and young people with obsessive-compulsive disorders to receive faster and more effective treatment.

02

Conditions studied

  • Obsessive-compulsive Disorder
03

In context

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

This study's planned enrollment of 625 is above the median of 133 across 86 observational studies indexed under Obsessive-Compulsive Disorder.

Browse Obsessive-Compulsive Disorder studies →

Lead sponsor

Susanne Walitza is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The sample consist of pupils with obsessive-compulsive disorder 4 to 18 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and young people from 8-18 years of age who fulfill the international classification of diseases tenth edition (ICD-10) , obsessive-compulsive disorder handled in our clinic.
  • Good German language speaking skills
  • IQ > 75
  • All study participants or their legal representative have given written permission for their experiences to be documented in the study.

Exclusion criteria

Exclusion Criteria:

  • Schizophrenia-related disorders (psychoses)
  • Missing data
  • Data sets without confirmed diagnosis
  • Purely consultaive patient interview (no therapy intervention prescribed)
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
625 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Symptoms severity of obsessive and compulsive symptoms in children and adolescents

    The clinician report questionnaire (BY-BOCS) contains 19 items designed to assess severity of obsessive and compulsive symptoms in children and adolescents.The test uses a four point scale to rate the severity of their obsessive compulsive behaviors. Higher score means a worse outcome.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Mar 2026, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2021
First posted
Jan 25, 2021
StartActual
May 1, 2020
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 1, 2026
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04723485
Lead sponsor
Susanne Walitza
Responsible party
Susanne Walitza (Head of the Department of Child and Adolescent Psychiatry, Psychiatric University Hospital, Zurich) — Sponsor-investigator
First posted
Jan 25, 2021
Start date
May 1, 2020
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
May 13, 2025

Study contacts

Susanne Walitza, Prof. Dr. med. Dipl.-Psych.
Contact
susanne.walitza@puk.zh.ch
+41 (0)43 499 26 26
Juliane Ball, Dr. rer. Nat. Dipl. Psych
Contact
juliane.ball@puk.zh.ch
+41 43 499 26 26
Susanne Walitza, Prof. Dr. med. Dipl.-Psych.
principal investigator · Sponsor-Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion